TONGHUA GOLDEN-HORSE(000766)2024-05-30 08:07Group 1: Company Development and Strategy - The company is focused on high-quality development to return value to shareholders and society [1][5] - The company is deepening its operations in the real economy and strengthening innovative economic value [5][6] - The company aims to establish a comprehensive elderly care industry chain through its new products [1][4] Group 2: New Drug Development - The new drug, Suheba Hydroamidine Tablets, has completed unblinding and statistical analysis reports, and will next submit a new drug application to the CDE [2][3][4] - The production capacity is designed to meet the domestic demand for Alzheimer's disease medication [4][5] - The company is following a set work plan to advance the new drug application as per CDE requirements [3][6] Group 3: Investor Concerns and Company Performance - Investors expressed concerns about the company's declining stock price and the lack of measures to stabilize it [5][6] - The company does not currently meet the conditions for dividend distribution [5][6] - The company reassured investors that all significant information will be disclosed in accordance with regulations [2][5] Group 4: Regulatory and Market Position - The new drug's statistical analysis report and clinical trial summary report are not subject to disclosure under stock listing rules [13][14] - The company is unable to provide a specific timeline for the new drug's market entry due to various factors, including market competition and pricing strategies [11][12] - The company is actively researching and planning for the future commercialization of the new drug [11][12]